Article

Dextromethorphan attenuation of postoperative pain and primary and secondary thermal hyperalgesia.

Post-Anesthesia Care Unit, Tel Aviv Sourasky Medical Center, and the Sackler Faculty of Medicine Tel Aviv University, Israel.
Canadian Journal of Anaesthesia (Impact Factor: 2.5). 03/2001; 48(2):167-74. DOI: 10.1007/BF03019730
Source: PubMed

ABSTRACT To determine the effect of 90 mg dextromethorphan (DM) p.o. vs placebo 90 min preoperatively, on the immediate and delayed postoperative course.
Thirty patients undergoing laparoscopic cholecystectomy or inguinal hernioplasty under general anesthesia were studied. Half (DM) received 90 mg dextromethorphan and half received placebo 90 min before anesthesia. Intravenous Patient Controlled Aanalgesia with morphine was available for two hours within a six-hour observation period; 75 mg diclofenac i.m. prn was given later in PACU and on-ward (24 hr). Pain was assessed using the visual analogue scales. Thermal thresholds for cold and hot sensation and for pain (by limit method) were evaluated at the site of skin incision (primary-) and distantly (secondary hyperalgesia). Von Frey filaments were applied testing touch sensation. Sedation level and morphine consumption were also assessed in PACU.
Demographic, surgical and perioperative parameters were similar; no untoward effects were encountered. Pain intensity and sedation were lower, and the feeling of well-being was greater, in the DM patients: one vs five (median), two vs five, five vs two, respectively, P <0.01 (90 min time-point). Thermal application revealed absence of primary and secondary hyperalgesia only in the DM patients; von Frey filaments induced similar pain sensation in both groups. Mean morphine/group, morphine/weight and diclofenac injection rates were approximately 55% lower in the DM group: 2.1 +/- 1.2 (SD) vs 4.7 +/- 2.3, 0.03 +/- 0.02 vs 0.07 +/- 0.03, 1.0 +/- 0.3 vs 2.4 +/- 0.2, respectively, P <0.01.
Compared with placebo, DM enabled reduction of postoperative analgesics consumption, improved well-being, and reduced sedation, pain intensity and primary and secondary thermal hyperalgesia.

0 Bookmarks
 · 
71 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Experimental studies suggest that surgical injury may up- or down-regulate nociceptive function. Therefore, the aim of this clinical study was to evaluate the effect of elective arthroscopically assisted knee surgery on nociceptive responses to a heat injury. Seventeen patients scheduled to undergo repair of the anterior cruciate ligament and 16 healthy controls were studied. The first burn injury was induced 6 days before surgery, and the second burn was induced 1 day after surgery with a contact thermode (12.5 cm2, 47 degrees C for 7 min) placed on the medial aspect of the calf contralateral to the surgical side. Ibuprofen and acetaminophen were given for 2 days before the first burn injury and again from the time of surgery. In the controls, the two burn injuries were separated by 7 days. Sensory variables included cumulated pain score during induction of the burn (visual analog scale), secondary hyperalgesia area, and mechanical and thermal pain perception and pain thresholds assessed before and 1 h after the burn injury. The heat injuries induced significant increases in pain perception (P < 0.001) and decreases in pain thresholds (P < 0.02). Baseline heat pain thresholds were higher during the second burn injury in patients (P < 0.001) and controls (P < 0.01). However, there were no significant differences in pain to heat injury (P > 0.8), secondary hyperalgesia areas (P > 0.1), mechanical and thermal pain perception (P > 0.1), or mechanical and thermal pain thresholds (P > 0.08) in the burn area before surgery compared to after surgery. Arthroscopic knee surgery did not modify nociceptive responses to a contralaterally applied experimental burn injury.
    Anesthesiology 11/2003; 99(5):1152-7. · 6.17 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives: Fibromyalgia syndrome [FMS], a poorly understood form of chronic pain, is under-diagnosed and under-treated. It is possible that stress-induced disturbances of endocrine and neurological systems underlie the ultimate expression of FMS. One of these systems, involving the N-Methyl-D-Aspartate [NMDA] receptor, is implicated in FMS as it is in other chronic pain conditions. Therefore, the objective of this review is to provide evidence for targeting the NMDA receptor for FMS pharmacotherapy and discuss its significance to FMS pain. Findings: Major barriers to effective management of FMS pain are the fact that there are no discrete objectifiable physical findings, psychological stress is often thought to be the sole explanation, and the pathophysiology of FMS pain remains unclear. Yet, an impressive body of evidence suggests that FMS pain is likely due to central sensitization. Given its role in central pain perception and processing, the NMDA receptor represents a possible lynchpin in the pathogenesis of chronic pain in FMS. Conclusions: We propose that the very centrality of NMDA receptors in chronic pain makes them an ideal target for pharmacotherapy in FMS. Reports of recent clinical trials using newer low-affinity NMDA receptor antagonists have shown analgesic affects in chronic pain states other than FMS. These new compounds represent novel avenues of research into the management of chronic pain.
    Journal of Musculoskeletal Pain 01/2010; 15(2):33-44. · 0.32 Impact Factor
  • Advances in Anesthesia 01/2009; 27(1):111-142.

Preview

Download
0 Downloads
Available from